Loading
companiesCompany
Aurigene Oncology
Dr. Reddy's oncology discovery company, with more than 20 programmes in clinical development worldwide through partners and its own small-molecule and cell therapy pipeline.
Overview
Aurigene was established in 2001 as a discovery subsidiary of Dr. Reddy's Laboratories and now describes itself as a clinical-stage biopharmaceutical company focused on cancer therapeutics, with more than 80 integrated discovery projects delivered, 22 programmes in global clinical development and a team of over 350 scientists in Bengaluru and Hyderabad. Its model has been to discover molecules against validated cancer targets and partner them with global companies for clinical development, while building an Indian pipeline that includes a BCMA-directed CAR-T for multiple myeloma developed for the Indian market.
Similar pages
- CompanyCartesian Therapeutics
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
- PersonNoopur Raje
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
- CompanyArcellx
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares BCMA, Multiple myeloma.
- CompanyPoseida Therapeutics
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
- TreatmentAnitocabtagene autoleucel
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
- PersonNikhil C. Munshi
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
- TreatmentAZD4045
Shares BCMA, Multiple myeloma.